

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Welireg	For renal cell carcinoma (RCC), added coverage for stage IV and relapsed disease per NCCN. For RCC, added requirement for clear cell histology and single agent use per NCCN. Added coverage for pheochromocytoma/paraganglioma per FDA label update and NCCN.	12/24/2025	Essential